Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab (2019) Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiss CA, Wirtz RM, Wach S, et al. Journal article Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors (2019) Moreira A, Loquai C, Pfoefer C, Kaehler KC, Knauss S, Heppt MV, Gutzmer R, et al. Journal article Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1 (2018) Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, et al. Journal article How to MEK the best of uveal melanoma: A systematic review on the efficacy and safety of MEK inhibitors in metastatic or unresectable uveal melanoma. (2018) Steeb T, Wessely A, Ruzicka T, Heppt MV, Berking C Journal article, Review article Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial (2018) Hurvitz SA, Quek RGW, Turner NC, Telli ML, Rugo HS, Mailliez A, Ettl J, et al. Journal article Influence of side-effects on early therapy persistence with letrozole in post-menopausal patients with early breast cancer: Results of the prospective EvAluate-TM study (2018) Nabieva N, Fehm T, Häberle L, De Waal J, Rezai M, Baier B, Baake G, et al. Journal article Treatment and outcomes of patients in the Brain Metastases in Breast Cancer Network Registry (2018) Witzel I, Laakmann E, Weide R, Neunhoeffer T, Park-Simon TJ, Schmidt M, Fasching P, et al. Journal article MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients (2018) Kirchberger MC, Ugurel S, Mangana J, Heppt MV, Eigentler TK, Berking C, Schadendorf D, et al. Journal article The proportion of circulating CD45RO+CD8+ memory T cells is correlated with clinical response in melanoma patients treated with ipilimumab (2017) Tietze JK, Angelova D, Heppt MV, Reinholz M, Murphy WJ, Spannagl M, Ruzicka T, Berking C Journal article Randomised, open-label, phase II study comparing the efficacy and the safety of cabazitaxel versus weekly paclitaxel given as neoadjuvant treatment in patients with operable triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE) (2017) Kuemmel S, Paepke S, Huober J, Schem C, Untch M, Blohmer JU, Eiermann W, et al. Journal article